MMJ Recs

NOVEMBER 30, 2023

While traditional treatments like antiepileptic drugs exist, they may not always provide adequate relief for all patients. In recent years, there has been growing interest in exploring alternative treatment options, and one that has gained attention is medical marijuana (MMJ).

Epilepsy 105

Epilepsy Treatment Patients Strains 105

Cannabis Law Report

AUGUST 23, 2021

Phase I clinical trial of the Satipharm CBD capsules in which results demonstrated the safety and high performance of the oral capsule technology, including the superior delivery profile of cannabidiol (CBD) compound to trial subjects. The treatment was generally well tolerated and the median reduction in seizures was 81.9%

Clinical Trials 105

Clinical Trials CBD Epilepsy Treatment 105

Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

Clinical Trials 75

Clinical Trials Research and Development Hybrid Medicine 75

Veriheal

AUGUST 28, 2023

And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. This treatment is believed to have long-lasting effects that can positively improve the quality of life and mental well-being of such individuals.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity. Silo Pharma Inc. Silo Pharma Inc.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Cannabis Law Report

JANUARY 11, 2023

PRESS RELEASE UK company Chanelle McCoy Health granted Ethics Approval to commence Phase III Efficacy Clinical Trial for the treatment of Sleep Disturbance CMH-CBD-001 using their Ultra Pure Synthetic Cannabinoid (CBD) formulation with pharmaceutical grade FDA registered raw material.

Clinical Trials 52

Clinical Trials CBD Sleep Pharmaceutical 52

The Cannigma

OCTOBER 11, 2021

No clinical trial was used in the compilation of the study. The researchers themselves wrote that the study is the first “to document self-reported efficacy of CBG-predominant products,” and provides further indication that “CBG-predominant cannabis-based medicines should be studied in randomized controlled trials.”.

Conditions 132

Conditions Clinical Trials Chronic Pain Cannabinoids 132

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. Quite frankly, the clinical trials couldn’t have come at a better time. About the Opioid Epidemic. Together, they work very well. Synergistically, they co-work on some of the same receptors.”.

Clinical Trials 116

Clinical Trials Chronic Pain Hydroponic Strains 116

Veriheal

JUNE 29, 2022

Psilocybin , a psychedelic compound found in a variety of mushrooms, has long been used as a tool to mitigate depression despite the limited amount of research on its efficacy and safety. Exploring Psilocybin and Treatment-Resistant Depression. Future Trials With COMP360 Psilocybin. Dr. David J.

Clinical Trials 105

Clinical Trials Blood Pressure Treatment Therapy 105

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

MMJ Recs

JULY 30, 2024

This has spurred interest in alternative treatments like treating PTSD with cannabis, which interacts with the body’s endocannabinoid system, implicated in stress regulation and emotional processing. However, these treatments do not work for everyone and may come with side effects or limited efficacy in managing symptoms long-term.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Puff Puff Post

DECEMBER 28, 2018

The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Instead, CBD is being used.

Treatment 76

Treatment Oil CBD Therapy 76

Medical Marijuana Program Connection

FEBRUARY 28, 2023

Incannex Healthcare Limited IXHL IHL has commenced a phase 2 clinical trial to assess the safety and efficacy of its. Read More

Clinical Trials 40

Clinical Trials Treatment Safety CBD 40

The Cannigma

MARCH 7, 2022

What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN. Those enrolled in the study will receive 28 days of treatment and then be assessed by pain-rating scales.

THC 139

THC Sleep Clinical Trials Cannabinoids 139

MMJ Recs

JULY 9, 2024

Traditional treatments, while helpful to some extent, often come with limitations and side effects that can further burden individuals already dealing with a debilitating disease. Medical marijuana has emerged as a promising alternative treatment option for managing symptoms associated with MS.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

AUGUST 22, 2021

The addition of methylated tryptamines with pending patent protection is focused on the potential improvement of treatments for mental health conditions including depression, anxiety and addiction, as well as other psychological and neurologic conditions. .” ” About PsyBio Therapeutics Corp. .

Clinical Trials 98

Clinical Trials Research and Development Treatment Conditions 98

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. Most types of epidermolysis bullosa are inherited. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. Most types of epidermolysis bullosa are inherited. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

The Blunt Truth

DECEMBER 23, 2020

assured, “The FDA’s first priority is to protect the health and safety of Americans. ” Importantly, the FDA, has not approved a marketing application for cannabis for the treatment of any disease or condition and thus has not determined that cannabis is safe and effective for any particular disease or condition.

CBD 103

CBD Food Safety Clinical Trials 103

Project CBD

NOVEMBER 11, 2023

So just on safety alone, it’s worth using it. And then cannabis has unique effects for a wide range of conditions, everything from the treatment of pain, treatment of asthma, treatment of immune conditions. You really can’t kill people with cannabis. You can’t say that about most other medicines.

Medicine 306

Medicine Research and Development Pharmaceutical Cannabis 306

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Peninsula Alternative Health

MAY 15, 2019

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response. tetrahydrocannabinol (THC).

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. Ketamine is also widely known as a popular party drug (“ Special K “).

Therapy 107

Therapy Legalization Chronic Pain DEA 107

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. This would answer questions about safety and efficacy, they said. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally.

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Canna Care Docs

OCTOBER 3, 2023

Conventional medication methods such as opiates may help terminal patients focus on more palliative treatment options and goals in order to better one’s comfort and overall quality of life during this time. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Otherside Farms

JANUARY 25, 2019

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

CannaMD

SEPTEMBER 28, 2020

However, there is a tradeoff between effectiveness and safety. Researchers are taking a new look at an ancient sleep treatment, Cannabis sativa , a plant long used to induce slumber. Scientists have also studied combinations of THC and CBD, such as Sativex clinical trials that show patients’ marked improvement in sleep.

Sleep 101

Sleep Clinical Trials Patients THC 101